Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis

par Jun Miyoshi, Tsubasa Maeda, Katsuyoshi Matsuoka, Daisuke Saito, Sawako Miyoshi, Minoru Matsuura, Susumu Okamoto, Satoshi Tamura, Tadakazu Hisamatsu
Publié 2021

Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis

par Natsuki Ishida, Satoshi Tamura, Takahiro Miyazu, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
Publié 2021

C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis

par Natsuki Ishida, Tomohiro Higuchi, Takahiro Miyazu, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
Publié 2021

Prevalence of UL97 gene mutations and polymorphisms in cytomegalovirus infection in the colon associated with or without ulcerative colitis

par Satoshi Tamura, Satoshi Osawa, Natsuki Ishida, Takahiro Miyazu, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Isao Kosugi, Takahisa Furuta, Ken Sugimoto
Publié 2021

Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation

par Satoshi Tamura, Natsuki Ishida, Takahiro Miyazu, Shunya Onoue, Shinya Tani, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
Publié 2020

Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease.

par Masaichi Kato, Ken Sugimoto, Kentaro Ikeya, Ryosuke Takano, Ai Matsuura, Takahiro Miyazu, Natsuki Ishida, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Takahisa Furuta, Hiroyuki Hanai
Publié 2021